E. M. Amin, S. Oltean, and J. Hua, WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing, Cancer Cell, vol.20, pp.768-780, 2011.

M. Ancelin, H. Buteau-lozano, and G. Meduri, A dynamic shift of VEGF isoforms with a transient and selective progesterone-induced expression of VEGF189 regulates angiogenesis and vascular permeability in human uterus, Proc Natl Acad Sci U S A, vol.99, pp.6023-6028, 2002.

K. Ballmer-hofer, A. E. Andersson, and L. E. Ratcliffe, Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output, Blood, vol.118, pp.816-826, 2011.

D. O. Bates, P. J. Catalano, and K. E. Symonds, Association between VEGF splice isoforms and progressionfree survival in metastatic colorectal cancer patients treated with bevacizumab, Clin Cancer Res, vol.18, pp.6384-6391, 2012.

D. O. Bates, T. G. Cui, and J. M. Doughty, VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma, Cancer Res, vol.62, pp.4123-4131, 2002.

D. O. Bates, P. P. Macmillan, and J. G. Manjaly, The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term, Clin Sci, vol.110, pp.575-585, 2006.

N. Beazley-long, J. Hua, and T. Jehle, VEGF-A165b Is an Endogenous Neuroprotective Splice Isoform of Vascular Endothelial Growth Factor A in Vivo and in Vitro, Am J Pathol, vol.183, pp.918-929, 2013.

M. J. Brauer, G. Zhuang, and M. Schmidt, Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies, Clin Cancer Res, vol.19, pp.3681-3692, 2013.

R. Catena, L. Larzabal, and M. Larrayoz, )(1)b and VEGF(1)(6)(5)b are weakly angiogenic isoforms of VEGF-A, Mol Cancer, vol.9, issue.1, pp.320-327, 2010.

R. Catena, V. Muniz-medina, and B. Moralejo, Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis, Int J Cancer, vol.120, pp.2096-2109, 2007.

C. Suarez, S. Pieren, M. Cariolato, and L. , A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2, Cell Mol Life Sci, vol.63, pp.2067-2077, 2006.

T. T. Chen, A. Luque, and S. Lee, Anchorage of VEGF to the extracellular matrix conveys differential signaling responses to endothelial cells, J Cell Biol, vol.188, pp.595-609, 2010.

C. Y. Cheung, M. Singh, and M. J. Ebaugh, Vascular endothelial growth factor gene expression in ovine placenta and fetal membranes, Am J Obstet Gynecol, vol.173, pp.753-759, 1995.

J. Ciura and P. P. Jagodzinski, Butyrate increases the formation of anti-angiogenic vascular endothelial growth factor variants in human lung microvascular endothelial cells, Mol Biol Rep, vol.37, pp.3729-3734, 2010.

C. D. Cohen, P. P. Doran, and S. M. Blattner, Sam68-like mammalian protein 2, identified by digital differential display as expressed by podocytes, is induced in proteinuria and involved in splice site selection of vascular endothelial growth factor, J Am Soc Nephrol, vol.16, pp.1958-1965, 2005.

T. G. Cui, R. R. Foster, and M. Saleem, Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein, Am J Physiol Renal Physiol, vol.286, pp.767-773, 2004.

C. J. David and J. L. Manley, Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged, Genes Dev, vol.24, pp.2343-2364, 2010.

R. Delcombel, L. Janssen, and R. Vassy, New prospects in the roles of the C-terminal domains of VEGF-A and their cooperation for ligand binding, cellular signaling and vessels formation, Angiogenesis, vol.16, pp.353-371, 2013.

R. Diaz, C. Pena, and J. Silva, Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis, Int J Cancer, vol.123, pp.1060-1067, 2008.

D. H. Dowhan, E. P. Hong, and D. Auboeuf, Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta, Mol Cell, vol.17, pp.429-439, 2005.

V. Edmond, C. Brambilla, and E. Brambilla, SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines, Cell Cycle, vol.10, pp.1968-1977, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02337383

V. Edmond, E. Moysan, and S. Khochbin, Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin, EMBO J, vol.30, pp.510-523, 2011.

A. P. Elias and S. Dias, Microenvironment changes (in pH) affect VEGF alternative splicing, Cancer Microenviron, vol.1, pp.131-139, 2008.

F. Fan, M. J. Gray, and N. A. Dallas, Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells, Mol Cancer Ther, vol.7, pp.3064-3070, 2008.

C. Faure, M. T. Linossier, and L. Malaval, Mechanical signals modulated vascular endothelial growth factor-A (VEGF-A) alternative splicing in osteoblastic cells through actin polymerisation, Bone, vol.42, pp.1092-1101, 2008.
URL : https://hal.archives-ouvertes.fr/ujm-00270279

N. Ferrara, Vascular endothelial growth factor: basic science and clinical progress, Endocr Rev, vol.25, pp.581-611, 2004.

R. Furumai, K. Uchida, and Y. Komi, Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF, Cancer Sci, vol.101, pp.2483-2489, 2010.

M. V. Gammons, O. Federov, and D. Ivison, Topical anti-angiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative-AMD, Invest Ophthalmol Vis Sci, vol.54, pp.6052-6062, 2013.

S. Gout, E. Brambilla, and A. Boudria, Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma, PLoS One, vol.7, p.46539, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02337424

R. Grepin, M. Guyot, and M. Jacquin, Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines, Oncogene, vol.31, pp.1683-1694, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00824206

J. Grunstein, J. J. Masbad, and R. Hickey, Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature, Mol Cell Biol, vol.20, pp.7282-7291, 2000.

A. Grutzkau, S. Kruger-krasagakes, and H. Baumeister, Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206, Mol Biol Cell, vol.9, pp.875-884, 1998.

P. Hamerlik, J. D. Lathia, and R. Rasmussen, Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth, J Exp Med, vol.209, pp.507-520, 2012.

S. J. Harper and D. O. Bates, VEGF-A splicing: the key to anti-angiogenic therapeutics?, Nat Rev Cancer, vol.8, pp.880-887, 2008.

P. S. Hegde, A. M. Jubb, and D. Chen, Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab, Clin Cancer Res, vol.19, pp.929-937, 2013.

K. A. Houck, N. Ferrara, and J. Winer, The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA, Mol Endocrinol, vol.5, pp.1806-1814, 1991.

K. A. Houck, D. W. Leung, and A. M. Rowland, Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms, J Biol Chem, vol.267, pp.26031-26037, 1992.

A. Jahangiri, D. Lay, M. Miller, and L. M. , Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance, Clin Cancer Res, vol.19, pp.1773-1783, 2013.

L. Jingjing, Y. Xue, and N. Agarwal, Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor, Invest Ophthalmol Vis Sci, vol.40, pp.752-759, 1999.

H. Kawai, Y. Minamiya, and M. Ito, VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of non-small cell lung carcinoma patients, Lung Cancer, vol.59, pp.41-47, 2008.

H. Kawamura, X. Li, and S. J. Harper, Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity, Cancer Res, vol.68, pp.4683-4692, 2008.

B. A. Keyt, L. T. Berleau, and H. V. Nguyen, The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency, J Biol Chem, vol.271, pp.7788-7795, 1996.

M. R. Ladomery, S. J. Harper, and D. O. Bates, Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm, Cancer Lett, vol.249, pp.133-142, 2007.

D. Lambrechts, H. J. Lenz, and S. De-haas, Markers of response for the antiangiogenic agent bevacizumab, J Clin Oncol, vol.31, pp.1219-1230, 2013.

H. Li, H. Yonekura, and C. H. Kim, Possible participation of pICln in the regulation of angiogenesis through alternative splicing of vascular endothelial growth factor receptor mRNAs, Endothelium, vol.11, pp.293-300, 2004.

N. Li, K. Kanda, and T. Fukumori, Expression of vascular endothelial growth factor isoforms and plateletderived endothelial cell growth factor in bladder cancer, Urol Oncol, vol.6, pp.10-15, 2000.

B. M. Lichtenberger, P. K. Tan, and H. Niederleithner, Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development, Cell, vol.140, pp.268-279, 2010.

B. Ljungberg, J. Jacobsen, and S. Haggstrom-rudolfssson, Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma, Urol Res, vol.31, pp.335-340, 2003.

K. V. Lu, J. P. Chang, and C. A. Parachoniak, VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex, Cancer Cell, vol.22, pp.21-35, 2012.

M. Manetti, S. Guiducci, and E. Romano, Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis, Circ Res, vol.109, pp.14-26, 2011.

M. Matsuyama, T. Chijiwa, and Y. Inoue, Alternative splicing variant of vascular endothelial growth factor-A is a critical prognostic factor in non-small cell lung cancer, Oncol Rep, vol.22, pp.1407-1413, 2009.

G. Merdzhanova, S. Gout, and M. Keramidas, The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo, Oncogene, vol.29, pp.5392-5403, 2010.

E. Miller-kasprzak and P. P. Jagodzinski, 5-Aza-2'-deoxycytidine increases the expression of anti-angiogenic vascular endothelial growth factor 189b variant in human lung microvascular endothelial cells, Biomed Pharmacother, vol.62, pp.158-163, 2008.

P. Mineur, A. C. Colige, and C. F. Deroanne, Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents, J Cell Biol, vol.179, pp.1261-1273, 2007.

S. Mourah, R. Porcher, and G. Lescaille, Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia, Int J Biol Markers, vol.24, pp.22-31, 2009.

Y. A. Muller, B. Li, and H. W. Christinger, Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site, Proc Natl Acad Sci U S A, vol.94, pp.7192-7197, 1997.

P. G. Nikolinakos, N. Altorki, and D. Yankelevitz, Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib, Cancer Res, vol.70, pp.2171-2179, 2010.

D. G. Nowak, E. M. Amin, and E. S. Rennel, Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis, J Biol Chem, vol.285, pp.5532-5540, 2010.

D. G. Nowak, J. Woolard, and E. M. Amin, Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors, J Cell Sci, vol.121, pp.3487-3495, 2008.

Y. Ohta, Y. Endo, and M. Tanaka, Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer, Clin Cancer Res, vol.2, pp.1411-1416, 1996.

Y. Oshika, M. Nakamura, and T. Tokunaga, Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer, Int J Oncol, vol.12, pp.541-544, 1998.

M. J. Pajares, J. Agorreta, and M. Larrayoz, Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung, J Clin Oncol, vol.30, pp.1129-1136, 2012.

Q. Pan, Y. Chanthery, and W. C. Liang, Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth, Cancer Cell, vol.11, pp.53-67, 2007.

Q. Pan, Y. Chathery, and Y. Wu, Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting, J Biol Chem, vol.282, pp.24049-24056, 2007.

Q. Pan, O. Shai, and L. J. Lee, Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing, Nat Genet, vol.40, pp.1413-1415, 2008.

M. Peiris-pages, S. J. Harper, and D. O. Bates, Balance of pro-versus anti-angiogenic splice isoforms of vascular endothelial growth factor as a regulator of neuroblastoma growth, J Pathol, vol.222, pp.138-147, 2010.

R. M. Perrin, O. Konopatskaya, and Y. Qiu, Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor, Diabetologia, vol.48, pp.2422-2427, 2005.

J. Plouet, F. Moro, and S. Bertagnolli, Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect, J Biol Chem, vol.272, pp.13390-13396, 1997.

R. O. Pritchard-jones, D. B. Dunn, and Y. Qiu, Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma, Br J Cancer, vol.97, pp.223-230, 2007.

Y. Qiu, C. Hoareau-aveilla, and S. Oltean, The anti-angiogenic isoforms of VEGF in health and disease, Biochem Soc Trans, vol.37, pp.1207-1213, 2009.

V. Ranpura, S. Hapani, and S. Wu, Treatment-related mortality with bevacizumab in cancer patients: a metaanalysis, JAMA, vol.305, pp.487-494, 2011.

E. S. Rennel, W. E. Guan, and H. , The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice, Br J Cancer, vol.98, pp.1250-1257, 2008.

E. S. Rennel, A. H. Varey, and A. J. Churchill, VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo, Br J Cancer, vol.101, pp.1183-1193, 2009.

R. Roskoski, Vascular endothelial growth factor (VEGF) signaling in tumor progression, Crit Rev Oncol Hematol, vol.62, pp.179-213, 2007.

T. Saito, N. Takeda, and E. Amiya, VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing, FEBS Lett, vol.587, pp.2179-2185, 2013.

F. A. Schutz, Y. Je, and C. J. Richards, Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors, J Clin Oncol, vol.30, pp.871-877, 2012.

X. Shi, M. Zhao, and W. K. Xie, Inhibition of neovascularization and expression shift of pro-/antiangiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model, Chin Med J (Engl), vol.126, pp.345-352, 2013.

S. Soker, H. Q. Miao, and N. M. , VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding, J Cell Biochem, vol.85, pp.357-368, 2002.

M. Tayama, T. Furuhata, and Y. Inafuku, Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer, World J Gastroenterol, vol.17, pp.4867-4874, 2011.

G. M. Tozer, S. Akerman, and N. A. Cross, Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors, Cancer Res, vol.68, pp.2301-2311, 2008.

A. H. Varey, E. S. Rennel, and Y. Qiu, VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy, Br J Cancer, vol.98, pp.1366-1379, 2008.

V. Vincenti, C. Cassano, and M. Rocchi, Assignment of the vascular endothelial growth factor gene to human chromosome 6p21, Circulation, vol.3, pp.1493-1495, 1996.

N. Vintonenko, I. Pelaez-garavito, and H. Buteau-lozano, Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions, Cell Adh Migr, vol.5, pp.332-343, 2011.

R. Wang, R. G. Crystal, and N. R. Hackett, Identification of an exonic splicing silencer in exon 6A of the human VEGF gene, BMC Mol Biol, vol.10, pp.103-109, 2009.

J. Woolard, W. Y. Wang, and H. S. Bevan, VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression, Cancer Res, vol.64, pp.7822-7835, 2004.

A. Yuan, C. Y. Lin, and C. H. Chou, Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE-and SSCE-MRI, PLoS One, vol.6, p.16062, 2001.

E. Zygalaki, L. Kaklamanis, and N. I. Nikolaou, Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease, Clin Biochem, vol.41, pp.82-87, 2008.

E. Zygalaki, E. G. Tsaroucha, and . Kaklamanis, Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer, Clin Chem, vol.53, pp.1433-1439, 2007.